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sions of the EQ-5D were assigned level 1 (no problems) as RLS
was not considered to affect a patient’s basic care and mobility.
For dimension with more than one mapped level, a rounded
average was considered. Other dimensions were assumed to be
captured by the IRLS instrument. Signiﬁcant inverse correlation
was reported between the changes in utility scores and the
changes in IRLS sum scores (p < 0.001). The regression model
explains 56% of the variance in the changes in the utility
scores: change_in_utility_scores = 0.0049 - 0.0277*change_in_
IRLS_sum_scores. Similar results were found in the analyses for
the changes from baseline to month 3. CONCLUSIONS:
Changes in the EQ-5D derived utility scores can be reasonably
estimated from the changes in the IRLS sum scores among
patients with restless legs syndrome.
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OBJECTIVES: To evaluate the appropriateness of the Child
Health Questionnaire—Parent Form 50 (CHQ-PF50) in moni-
toring behavioral and emotional functioning in children with
epilepsy treated with antiepileptic drugs (AEDs), by comparing
and correlating it with the Child Behavior Checklist (CBCL).
METHODS: Clinical data from a double-blind placebo (PBO)
controlled study of adjunctive therapy of levetiracetam (20–
60 mg/kg/day) in children (4–16y) with partial onset seizures
(POS), which included the CBCL and the CHQ-PF50 to assess
behavioral and emotional functioning, were used. Pearson cor-
relation coefﬁcients between scores of the two instruments mea-
suring similar concepts were calculated, and the two instruments
were compared for item content, acceptability, reliability, validity
and responsiveness to various factors. RESULTS: 78 patients had
CHQ-PF50 and CBCL data at baseline and evaluation (12
weeks). Both questionnaires showed good acceptability in terms
of return rates (81.6% at the lowest) and missing data (average/
patient < 1%). All subscales except CHQ-PF50 General Health
showed good reliability in terms of Crohnbach’s a (r > 0.700).
All scores of the CHQ-PF50 measuring behavioral or emotional
functioning (Behavior, Mental Health, Role/Social Limitations-
Emotional/Behavioral and the Psychosocial Summary Score)
showed large correlations with CBCL scores measuring similar
concepts (-0.821 < -0.433) at baseline but smaller correlations
for change from baseline (-0.470 < -0.030). CHQ-PF50
behavior-related scores seemed more responsive to the occur-
rence of behavioral adverse events than corresponding CBCL
scores, although both showed limited sensitivity (small Standard-
ized Response Means). The CBCL Externalizing score, however,
appeared to be more sensitive when comparing treatment groups
than the corresponding CHQ-PF50 Behavior score (p = 0.011 vs.
p = 0.871 from ANCOVA). CONCLUSIONS: The CHQ-PF50
scores assessing behavioral and emotional functioning have
shown good reliability, validity, and high consistency with the
corresponding CBCL scores. However, the behavior score of the
CHQ-PF50 appeared to be less sensitive in showing between-
treatment group differences than the more speciﬁc and compre-
hensive Externalizing score of the CBCL.
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OBJECTIVES: To evaluate patient and physician satisfaction
with the use of a Brief Dementia Screening test for Parkinson’s
disease (PD-BDST) in a clinical practice setting. METHODS:
An observational, cross-sectional and multicenter study was
conducted, including 471 PD patients. The PD-BDST and Mini-
Mental State Examination (MMSE) were administered to
patients. A patient satisfaction questionnaire rated with a visual
scale from 0 to 10 was used to assess patient satisfaction. Phy-
sician satisfaction (n = 52) was measured using a satisfaction
questionnaire rated with a Likert scale from 0 to 5. RESULTS:
The mean PD-BDST score (SD) was 18.5  6.3, and 36.3%
of patients presented scores compatible with dementia (PD-
BDST score 15 points). There was a high correlation between
the score of the Mini-Mental test (29.05  5.4) and the
PD-BDST scores (r = 0.73, p < 0.001). Mean satisfaction scores
for patients and physician were 27.6  7.4 and 3.60  0.58,
respectively. A total of 37.7% of patients reported not having
any trouble completing the test, and 22.6% expressed difﬁcul-
ties in only one part of the test. The proportion of satisﬁed
patients was 77.3%. Patients with the least risk of poor satis-
faction were those with a PD-BDST higher score (OR = 0.9) and
those reporting less difﬁculties completing the test (OR = 0.8).
More than half of physicians presented a score higher than
3.73. The mean scores for PD-BDST applicability, handling and
reliability of physicians were 3.5  0.7, 3.7  0.6 y 3.1  0.5.
CONCLUSIONS: Previous studies have shown the PD-BDST to
be a speciﬁc test to diagnose PD-related dementia able to dis-
tinguish between healthy controls, non-demented PD and
demented PD. In the present study, PD patients found the
PD-BDST satisfactory. Participating investigators considered the
test to be valid, quick and simple to administer in a clinical
practice setting.
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OBJECTIVES: Insomnia is prevalent in many populations, both
as a primary disorder and as a symptom secondary to a medi-
cation or underlying condition. The objective of this study was
to assess patient satisfaction with a variety of insomnia medi-
cations used in a community-based population in the U.S.
METHODS: Patients are recruited from multiple sources
including physician, pharmacy and online referrals and asked to
report ongoing medications on the project website (www.
iGuard.org). A random sample of patients are contacted to
complete the Treatment Satisfaction Questionnaire for Medica-
tion Version 1.4 (TSQM), a 14-item reliable and valid instru-
ment to assess patients’ satisfaction with medication, providing
scores on four scales—effectiveness, side effects, convenience
and global satisfaction. TSQM scores range from 0 to 100, with
higher scores indicating higher satisfaction on the domain.
Analyses were conducted to explore differences in patient sat-
isfaction across insomnia medications. RESULTS: A total of
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239 patients on eight different insomnia medications were
included: alprazolam (30), amitriptyline (33), eszopiclone (30),
melatonin (30), quetiapine (30), temazepam (27), trazodone
(30) and zolpidem (29). The mean age (SD) of the patients was
49.3 years (SD = 11.8): 78.2% were female, 68.6% Caucasian,
23.0% Hispanic and 2.9% Black. The TSQM domains had
good internal consistency, with Cronbach’s alpha for all
domains exceeding 0.83. After adjusting for patient age, race,
gender, self-reported severity and Bonferroni correction for mul-
tiple comparisons, patients on products for secondary insomnia
expressed lower TSQM scores than patients on products for
primary insomnia. Some differences were also observed when
comparing TSQM scores for individual medication with the
mean score from all patients. For example, patients on amitrip-
tyline had a signiﬁcantly lower score on effectiveness (p = 0.044)
while patients on quetiapine had a signiﬁcantly lower score on
side effects (p = 0.0005). CONCLUSIONS: When selecting an
insomnia medication, clinicians should consider the patient’s
underlying condition as well as differences in patient satisfaction
with insomnia medications.
NEUROLOGICAL DISORDERS—Health Care Use &
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OBJECTIVES:To assess the AntiEpileptic Drugs (AED) usage and
the prevalence of AED users in Campania, a region of approxi-
mately 5.8million inhabitants in the south of Italy during the years
2005–2006. METHODS: We collected, from an electronic
research database, all prescriptions for AEDs reimbursed in the
years 2005–2006 in 8 local-health-authorities (70% of the overall
population) of Campania. We calculated the number of subjects
receiving more than a single AED prescription, to estimate the
annual prevalence of AED users. Therefore we excluded users of
morphine-like analgesic (ATC-code N02A). Annual prevalence of
AED use was assessed in the entire sample, stratiﬁed by drug type
and age group. RESULTS: We identiﬁed 107,959 subjects. The
estimated crude 1-year prevalence of AED use increased from
16.6/1000 (53.0 % female) in 2005 to 19.5/1000 (54.4% female)
in 2006. Prevalence increased with age for both genders. Preva-
lence of AED use increased from 5.9/1000 in 2005 to 8.7/1000 in
2006 for ‘new’ AEDs while was stable for ‘old’ AEDs (8.4/1000 in
2005, 8.2/1000 in 2006), excluding association between old-new
and switchers. Themost frequent regimens were all monotherapy:
phenobarbital, gabapentin, valproic acid, carbamazepina, lamot-
rigina were the most common AED in monotherapy in 2005,
pregabalin became ﬁrst in 2006when gabapentin went off-patent.
CONCLUSIONS: The results of the study indicate an increasing
prevalence of AED use with special reference to ‘newer’ com-
pounds. The increase is mainly due to pregabalin, marketed in the
end of 2004 with indications for epilepsy and neuropathic pain.
Excluding pregabalin and gabapentin, commonly used for the
treatment of neuropathic pain, older AEDs are the most frequent
regimens. Probably older AEDs remain the ﬁrst line treatment for
epileptic disorders. This claim is in accordance with a previous
study conducted in Italy from a General-Practitioners database
(Savica et al., European Journal of Neurology, 2007).
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OBJECTIVES: One of the consequences of an aging population
is the emerging importance of genetically-linked disorders which
develop in later life. Many of these disorders affect the central
nervous system and result in progressive degeneration of higher
functions and dementia. This research expands on observations
described in a previous presentation (PMC53, ISPOR 2008) con-
cerning the inﬂuence of genetic discoveries on the number of
probable RCTs in Alzheimer’s disease (AD) and Huntington’s
disease (HD) to explore other measures of interest. METHODS:
A citation search was conducted in Medline for the years 1951 to
2005 (5-yearly time periods). Search ﬁlters for RCTs, economic
studies (ES), and observational studies (OS) (www.sign.ac.uk/
methodology/ﬁlters.html) combined with search strings incorpo-
rating the MeSH terms for each disorder were run to provide an
estimate of interest in these disorders. The x-fold increases
(2001–2005/1976–1980) were calculated and the data were
analysed using logistic regression. RESULTS: There were
12,820,265 publications during 1951 to 2005, with 57,466 relat-
ing to AD and 8304 relating to HD. Over the past 30 years the
interest in AD has been increasing, with 62-fold increases in the
number of papers published within this disease area. In contrast,
during the same time period publications in HD showed only a
4-fold increase. This disparity is particularly notable for probable
RCTs, where there were 405-fold increases in AD but only 5-fold
increases in HD. Interestingly the interest in AD predates the
identiﬁcation of several genetic linkages that occurred in the late
1990’s. Conversely, the discovery of huntingtin in 1993 appears
to have had little effect on interest in HD. CONCLUSIONS:
Improvements and advances in sanitation, nutrition and immu-
nisation against infectious diseases have combined with other
factors to reduce mortality and prolong life expectancies. One of
the most important consequences of increased life expectancy is
the emergence of genetically linked disorders which develop in
later life. Discovery of genetic linkage does not appear to be a
strong predictor of research activity, in the case of AD and HD.
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OBJECTIVES: To determine the general referral and neurologi-
cal rate per center and the adjusted efﬁciency indexes, through
the retrospective implementation of the Adjusted Clinical Groups
(ACG) in a primary care setting. METHODS: Design
multicenter-retrospective study. Attended patients by ﬁve
primary care teams (PCT) during the year 2006 were included.
The main measurements were general parameters, age, gender,
dependent (visits and episodes) and morbidity of each patient
relative to each ACG. The referral rate was deﬁned as the quo-
tient between the number of referrals and the visits made. Efﬁ-
ciency Index (EI) was established dividing the observed by the
expected referrals obtained by indirect standardization. Statisti-
cal signiﬁcance: p < 0.05. RESULTS: Studied patients 80775
(use: 72.4%), 4.8  3.5 episodes and 7.9  8.2 visits/patient/
year. Percentage of visits with a referral was 9.0% (conﬁance
interval [CI]: 8.8–9.2); age: 44.8  22.8 years (women: 54.6%),
A608 Abstracts
